Pittsburgh, PA · Founded 2013 · Privately Held (backing)
Developer of a therapeutic and drug discovery peptide platform designed to treat multidrug-resistant bacterial infections. Peptilogics is based in Pittsburgh, PA and was founded in 2013. It was valued at $150 million at its later-stage round in May 2025, the last priced event on record. It has raised $195 million across 4 recorded rounds; the latest was a $35.8 million early-stage round in Dec 2020.
PMV mark · valuation
$150.0M
Oct 2026
Priced at
its later-stage round
May 2025
Total raised
$194.8M
Last round
Early Stage VC
Dec 2020
No prints on record
No secondary trades in Peptilogics shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Peptilogics with a free account
·The complete investor list: 30 names
·Watch Peptilogics: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Peptilogics stock.
